Abishek Chandrashekar

Abishek Chandrashekar

Auto-generated profile, based on publicly available information

Abishek Chandrashekar

Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2020 in Nature
Verified
Journal Article
Closed access
PDF file
KMKatherine McMahan
Katherine McMahan
JYJingyou Yu
Jingyou Yu
NMNoe Bladimir Mercado
Noe Bladimir Mercado
CLCarolin Loos
Carolin Loos
LTLisa H. Tostanoski
Lisa H. Tostanoski
DBDan H. Barouch
Dan H. Barouch

15 July 2020 in Nature
Verified
Journal Article
Closed access
PDF file
SZSeth J. Zost
Seth J. Zost
PGPavlo Gilchuk
Pavlo Gilchuk
JCJames Brett Case
James Brett Case
EBElad Binshtein
Elad Binshtein
RCRita E. Chen
Rita E. Chen
JCJames E. Crowe
James E. Crowe

14 August 2020 in Science
Verified
Journal Article
Open access
PDF file
JYJINGYOU YU
JINGYOU YU
LTLisa H. Tostanoski
Lisa H. Tostanoski
LPLauren Peter
Lauren Peter
NMNoe Bladimir Mercado
Noe Bladimir Mercado
KMKatherine McMahan
Katherine McMahan
DBDan H. Barouch
Dan H. Barouch
Prototype DNA vaccines for SARS-CoV-2: The development of a vaccine to protect against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an urgent biomedical need. Yu et al. designed a series of prototype DNA vaccines against the SARS-CoV-2 spike protein, which is used by the virus to bind and invade human cells. Analysis of the vaccine candidates in rhesus macaques showed that animals developed protective humoral and cellular immune responses when challenged with the virus. Neutralizing antibody titers were also observed at levels similar to those seen in humans who have recovered from SARS-CoV-2 infection. Science , this issue p. 806

30 July 2020 in Nature
Verified
Journal Article
Closed access
PDF file
NMNoe Bladimir Mercado
Noe Bladimir Mercado
RZRoland Zahn
Roland Zahn
FWFrank Wegmann
Frank Wegmann
CLCarolin Loos
Carolin Loos
ACAbishek Chandrashekar
Abishek Chandrashekar
DBDan H. Barouch
Dan H. Barouch

14 August 2020 in Science
Verified
Journal Article
Open access
PDF file
ACAbishek Chandrashekar
Abishek Chandrashekar
JLJinyan Liu
Jinyan Liu
AMAmanda J. Martinot
Amanda J. Martinot
KMKatherine McMahan
Katherine McMahan
NMNoe Bladimir Mercado
Noe Bladimir Mercado
DBDan H. Barouch
Dan H. Barouch
Immunity from reinfection: One of the many open questions about severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is whether an individual who has cleared the virus can be infected a second time and get sick. Chandrashekar et al. and Deng et al. generated rhesus macaque models of SARS-CoV-2 infection and tested whether natural SARS-CoV-2 infection could result in immunity to viral rechallenge. They found that animals indeed developed immune responses that protected against a second infection. Although there are differences between SARS-CoV-2 infection in macaques and in humans, these findings have key implications for public health and economic initiatives if validated in human studies. Science , this issue p. 812 , p. 818

9 September 2016 in Science
Verified
Journal Article
Closed access
PDF file
PAPeter Abbink
Peter Abbink
RLRafael A. Larocca
Rafael A. Larocca
RBRafael A. De La Barrera
Rafael A. De La Barrera
CBChristine A. Bricault
Christine A. Bricault
EMEdward T. Moseley
Edward T. Moseley
DBDan H. Barouch
Dan H. Barouch
Zika virus (ZIKV) is responsible for a major ongoing epidemic in the Americas and has been causally associated with fetal microcephaly. The development of a safe and effective ZIKV vaccine is therefore an urgent global health priority. Here we demonstrate that three different vaccine platforms protect against ZIKV challenge in rhesus monkeys. A purified inactivated virus vaccine induced ZIKV-specific neutralizing antibodies and completely protected monkeys against ZIKV strains from both Brazil and Puerto Rico. Purified immunoglobulin from vaccinated monkeys also conferred passive protection in adoptive transfer studies. A plasmid DNA vaccine and a single-shot recombinant rhesus adenovirus serotype 52 vector vaccine, both expressing ZIKV premembrane and envelope, also elicited neutralizing antibodies and completely protected monkeys against ZIKV challenge. These data support the rapid clinical development of ZIKV vaccines for humans.